Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab or Urelumab +/- Nivolumab in Recurrent GBM
NCT02658981Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2016
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of relatlimab and urelumab in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2016; status: completed.
02
Drugs
relatlimaburelumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02658981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658981.